Status:
COMPLETED
D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement
Lead Sponsor:
Centre for Addiction and Mental Health
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Pathological Gambling
Eligibility:
All Genders
19-65 years
Phase:
PHASE2
Brief Summary
To determine if: 1. pathological gambling is similar to psychostimulant addiction as reflected by parallel roles for D1 and D2 receptors in gambling and stimulant reinforcement. 2. these parallel rol...
Detailed Description
BACKGROUND: No previous research appears to have investigated the role of dopamine (DA) D1 or D2 receptors in psychostimulant reinforcement in pathological gamblers. Effects of haloperidol vs. placebo...
Eligibility Criteria
Inclusion
- PATHOLOGICAL GAMBLERS
- otherwise healthy, non-treatment seeking, non-abstinent
- male or female
- ages 19-65
- DSM-IV PG symptom scale score \> 5
- SOGS (South Oaks Gambling Screen) score \> 5
- nicotine dependence acceptable
- CONTROLS
- healthy
- male or female
- ages 19-65
- DSM-IV PG symptom scale score = 0
- SOGS score = 0
- nicotine dependence acceptable
- must have played slot machine \> 5 times
Exclusion
- both Pathological Gamblers and Controls
- Axis I psychopathology aside from nicotine dependence (or PG) based on SCID
- Schizotypal or Borderline Personality Disorder based on psychiatric interview
- Family history of schizophrenia or bipolar disorder
- English comprehension below grade 7 level.
- ADS (Alcohol Dependence Scale) \> 13 (more than low dependence)
- BDI (Beck Depression Inventory) short form \> 10 (more than low depression)
- DAST (Drug Abuse Screening Test) \> 4 (possible drug abuse)
- Consumption of \> 20/15 (men/women) standard alcoholic drinks/ week (hazardous drinking)
- Smoking \> 20 cigarettes/day to help minimize withdrawal symptoms during test phase
- Any prior use of psychostimulant drugs
- Current use of medication that could interact with any of the study medications
- Women who are pregnant or breastfeeding
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02203786
Start Date
September 1 2009
End Date
September 1 2015
Last Update
April 25 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5S 2S1